ITM-91 by ITM Isotope Technologies Munich for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Researchers aim to transform treatment for sleep disorders in military personnel

Traditional solutions for sleep disorders, including medications and cognitive behavioral therapies, often provide insufficient relief for military personnel, a problem researchers from the University of

November 1, 2024

Study provides insight into how low-dose ketamine alleviates symptoms of major depression

University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug,

November 19, 2024

PEPFAR has been a lifeline in Ukraine. Now it’s under threat

In Ukraine, a little bit of good news can go a long way, and the lifesaving work being done as a result of the President’s Emergency

December 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.